Table 2. AR amplification status in CTCs from mCRPC patients (related to Figure 3).

Study #	Serum PSA at bx	Total # CTCs	# WT CTC	# Amplified CTCs	% of Amplified CTCs
14–114	94.42	19	18	1	5.2
14–11	1.79	12	10	2	16.7
14–74	17.56	27	10	7	25.9
14–99	2137.3	18	13	5	27.8
14.32	1169	13	8	5	38.4
14–104	332.62	57	33	24	42.1
14–87	1859	2	1	1	50
14–77	11.82	48	23	25	52
14–109	425.28	551	22	29	56.9
14–76	4.54	40	11	29	72.5
14–108	10.57	79	21	58	73.4
14–86	120.06	26	6	20	76.9
14–72	37.06	20	20	0	0
14–89	6.18	18	18	0	0
14–88	173.5	6	6	0	0
14–58	48.92	4	4	0	0
14–90	148.39	4	4	0	0
14–106	371.76	1	1	0	0
14–51	109.93	2	0	2	100
14–59	215.9	8	0	8	100
14–4	250	3	0	3	100
14–103	8.33	5	0	5	100
14–116	20.9	40	0	40	100
14–50	41.83	1	0	1	100